Here you will find the Publications from 2010 onwards that were produced at IfADo.
Comparative metabolism of aflatoxin B1 in mouse, rat and human primary hepatocytes using HPLC-MS/MS. Arch Toxicol 97: 3179-3196 (2023)
PBTK modeling of the pyrrolizidine alkaloid retrorsine to predict liver toxicity in mouse and rat. Arch Toxicol 97: 1319–1333 (2023)
Sublethal necroptosis signaling promotes inflammation and liver cancer. Immunity 56: 1578-1595.e8 (2023)
The hepatocyte export carrier inhibition assay improves the separation of hepatotoxic from non-hepatotoxic compounds. Chem Biol Interact 351: 109728 (2022) (16 pp)
Influence of bile acids on the cytotoxicity of chemicals in cultivated human hepatocytes. Toxicol In Vitro 81: 105344 (2022)
Stimulation of de novo glutathione synthesis by nitrofurantoin for enhanced resilience of hepatocytes. Cell Biol Toxicol 38: 847-864 (2022)
In vitro/in silico prediction of drug induced steatosis in relation to oral doses and blood concentrations by the Nile Red assay. Toxicol Lett 368: 33-46 (2022)
Hypoalbuminemia affects the spatio-temporal tissue distribution of ochratoxin A in liver and kidneys: consequences for organ toxicity. Arch Toxicol 96: 2967–2981 (2022)
Comparing in vitro human liver models to in vivo human liver using RNA-Seq. Arch Toxicol 95: 573–589 (2021)
Subcellular spatio-temporal intravital kinetics of aflatoxin B1 and ochratoxin A in liver and kidney. Arch Toxicol 95: 2163-2177 (2021)
The EU-ToxRisk method documentation, data processing and chemical testing pipeline for the regulatory use of new approach methods. Arch Toxicol 94: 2435-2461 (2020)
Hepatotoxicity of anesthetic gases. (Letter to the editor). EXCLI J 19: 1052-1053 (2020)
Which concentrations are optimal for in vitro testing? (Letter to the editor). EXCLI J 19: 1172-1173 (2020)
Handling deviating control values in concentration-response curves. Arch Toxicol 94: 3787–3798 (2020)
Highlight report: Role of PD-L1 in never-smokers. EXCLI J 18: 439-441 (2019)